

CRDP

Provider Bulletin

March 6, 2009

FORMULARY ADDITION: Renvela®

Effective immediately, Renvela® is available via the Program's medical exception process.

Medical Exception Criteria are:

- Prior trial of phosphate lowering therapy with an inability to control phosphate.
- A calcium phosphate product equal to or greater than 70mg²/dl².
- Signature of Facility Dietician/Nutritionist indicating that the patient has been educated about dietary restrictions necessary to maintain control of phosphate levels.

Upon approval of a medical exception, CRDP will reimburse up to a maximum of 9 capsules or 7,200mg daily.

FORMULARY DELETION: Effective May 4, 2009

Renagel®

Beginning September 30, 2009, Renagel® will no longer be manufactured. In anticipation of this action, Renagel® will be deleted from the CRDP formulary effective May 4, 2009. Cardholders currently receiving Renagel® via the medical exception process will have this medical exception automatically applied to Renvela®.

Questions may be directed to Provider Services at
1-800-835-4080.